Last updated
Revenue
R&D Expenses
Operating CF
Total Assets
Total Liabilities
Equity
Shares Out.
D/E Ratio
Dilution Watch
Financials
52W LOW $27.0052W HIGH $55.67
Volume
848.43 K
Value Traded
74.35 M
Short % Float
9.31%
-3.34%Week
-11.11%1 Month
-22.3%3 Month
+20.97%6 Month
+67.27%5 Year
+569.09%All Time
Cash Data
- Monthly Burn
- Burn Trend
- Dilution Risk
- SEC Filing
Key Stats
Market Cap
6.82 B
EPS (TTM)
0.39
P/E Ratio
102.40
Ent. Value
7.68 B
Total Shares
167.76 M
Float Shares
162.77 M
Insiders
2.98%
Institutions
105.32%
Upcoming Catalysts
FDA decisions, readouts and PDUFA dates · scored by probability of approval
PoA blends historical approval base rates, trial design score and FDA review track record.
ALKS Catalyst Timeline
Dated clinical, regulatory and corporate events for Alkermes plc
Catalyst Timeline
Dated clinical, regulatory & corporate events for Alkermes plc
367Total events
13Upcoming
126Tier-1 (high impact)
2017 to 2033Coverage
Upcoming catalysts 2
Event history 50
▲Topline ReadoutClinical Data
Positive Phase 1b topline results of ALKS 7290 in adults with ADHD
Attention-Deficit Hyperactivity Disorder (ADHD)source ↗
▲Primary Endpoint MetClinical Data
ALKS 7290 generally well tolerated at all doses tested in healthy volunteers and adults with ADHD
Attention-Deficit Hyperactivity Disorder (ADHD)source ↗
▲Additional DataClinical Data
ALKS 7290 demonstrated clinically meaningful improvements on AISRS and CGI-S at day 14
Attention-Deficit Hyperactivity Disorder (ADHD)source ↗
▲Biomarker DataClinical Data
ALKS 7290 showed treatment effects across cognitive domains including processing speed, working memory and attention
Attention-Deficit Hyperactivity Disorder (ADHD)source ↗
▲Safety Data UpdateClinical Data
No serious TEAEs reported; most TEAEs mild; no discontinuations among ALKS 7290-treated participants
Attention-Deficit Hyperactivity Disorder (ADHD)source ↗
▲Enrollment UpdateTrial
Phase 2 study of ALKS 7290 in adults with ADHD is currently enrolling
Attention-Deficit Hyperactivity Disorder (ADHD)source ↗
▲Grant / FundingCorporate
Alkermes opens applications for 9th Annual Pathways Research Awards, grants up to $100,000 per project
schizophrenia, bipolar I disorder, narcolepsy type 1 and 2, idiopathic hypersomniasource ↗
▲First Patient DosedTrial
First participant dosed in Phase 2 study of ALKS 7290 in adults with ADHD
Attention-Deficit Hyperactivity Disorder (ADHD)source ↗
▲Trial InitiationalixorextonTrial
Brilliance Studies in NT1 and NT2 recently initiated
narcolepsy type 1 and type 2source ↗
▲PublicationalixorextonPresentation
Vibrance-1 Phase 2 data for alixorexton in NT1 published in The Lancet Neurology
narcolepsy type 1 (NT1)source ↗
▲Interim AnalysisalixorextonTrial
Planned interim analysis of LTE study shows sustained improvement in wakefulness
narcolepsy type 1 and type 2source ↗
▲Oral PresentationalixorextonPresentation
Detailed positive results from Vibrance-2 Phase 2 study presented at SLEEP 2026
Narcolepsy Type 2source ↗
●Oral PresentationPresentation
Alkermes to participate in Goldman Sachs 47th Annual Global Healthcare Conference
◆Oral PresentationPresentation
Data presentations at Spring 2026 scientific conferences
psychiatrysource ↗
▲Topline ReadoutLUMRYZApprovedClinical Data
Positive topline results from REVITALYZ Phase 3 study of LUMRYZ in idiopathic hypersomnia
idiopathic hypersomniasource ↗
▲Primary Endpoint MetLUMRYZApprovedClinical Data
Primary endpoint met: ESS improvement vs placebo (p<0.0001)
idiopathic hypersomniasource ↗
◆Poster PresentationalixorextonPresentation
Poster presentation of Vibrance-1 patient-reported outcomes at AAN 2026
narcolepsy type 1source ↗
◆Oral PresentationalixorextonPresentation
Additional data from Vibrance-1 Phase 2 study of Alixorexton to be presented at AAN 2026
Narcolepsy Type 1source ↗
◆PublicationLYBALVIApprovedPresentation
Long-term analysis of LYBALVI effects on negative symptoms published in The Journal of Clinical Psychiatry
schizophreniasource ↗
▲Trial InitiationalixorextonTrial
Initiation of Phase 3 Brilliance NT1 Study 304
narcolepsy type 1source ↗
◆Topline ReadoutLUMRYZApprovedClinical Data
Data expected from REVITALYZ LUMRYZ idiopathic hypersomnia phase 3 study
idiopathic hypersomniasource ↗
●Enrollment MilestonealixorextonTrial
Complete enrollment of once-daily dosing arms in Vibrance-3
idiopathic hypersomniasource ↗
◆Oral PresentationPresentation
Alkermes management to present at TD Cowen 46th Annual Health Care Conference
▲Breakthrough Therapy DesignationalixorextonDesignation
Alixorexton granted Breakthrough Therapy designation by FDA for NT1
narcolepsy type 1source ↗
▲Primary Endpoint MetalixorextonClinical Data
Vibrance-1 met primary endpoint: statistically significant improvement in MWT
narcolepsy type 1source ↗
◆Trial InitiationalixorextonTrial
Planned phase 3 program initiation for alixorexton in narcolepsy
narcolepsysource ↗
●End Of Phase 2 MeetingalixorextonFDA Meeting
End-of-phase 2 meeting with FDA for alixorexton
narcolepsysource ↗
▲Primary Endpoint MetalixorextonClinical Data
Alixorexton met dual primary endpoints in Phase II Vibrance-1 study for NT2
narcolepsy type 2source ↗
▲Primary Endpoint MetalixorextonClinical Data
Positive topline results: alixorexton met dual primary endpoints (MWT and ESS) in Vibrance-2
narcolepsy type 2source ↗
●Oral PresentationalixorextonPresentation
Investor webcast to discuss Vibrance-2 results
narcolepsy type 2source ↗
●Quarterly UpdateCorporate
Avadel Q3 2025 earnings release indicates deal likely to close in Q1 2026
◆Topline ReadoutalixorextonClinical Data
Topline results from Vibrance-2 phase 2 study of alixorexton in narcolepsy type 2 expected next month
narcolepsy type 2source ↗
▲Quarterly UpdateCorporate
Alkermes reports Q3 2025 financial results with revenues of $394.2M
▲Oral PresentationalixorextonPresentation
Positive data from Vibrance-1 phase 2 study of alixorexton in narcolepsy type 1 presented
narcolepsy type 1source ↗
Past FDA Catalysts and PDUFA Decisions
How ALKS actually traded into and out of each decision
| Date | Drug | Catalyst | Stage | Reaction | Event Move % | Best Trade % |
|---|---|---|---|---|---|---|
| 2025-09-30 | Alixorexton (formerly referred to as ALKS 2680) | Phase 2 data readout | Phase 2 |
Reaction: 30 trading days around the event · Event Move: close to close on decision day · Best Trade: peak run-up from entry 10 days before the decision
Drug Pipeline Intelligence
C50 / 100
Pipeline Score
$523M
Pipeline Value
$7.3B
Commercial Value
Fair Value
Valuation Signal
4
Drugs Scored
0.3x
rNPV / MCap
Top 17%
Small Cap(rank 113 of 658)
Percentile Rank
Alkermes plc carries a moderate pipeline score (50/100), with $804M risk-adjusted pipeline value, led by ALKS 7290 in Attention Deficit Disorder With Hyperactivity (ADHD) (Phase 2).
Commercial products (revenue basis: trailing 4 quarters of total revenue (10-K and 10-Q), to Jun 2026; product lines: last four quarters to Jun 2026 (10-K and 10-Q)) Revenue $1.7B x 4.4 = $7.3B
| Product | Revenue | Prior period | Change |
|---|---|---|---|
| VIVITROL | $482M | $470M | +2.5% |
| ARISTADA and ARISTADA INITIO | $386M | $356M | +8.4% |
| LYBALVI | $379M | $306M | +23.8% |
| LUMRYZ | $136M | - | - |
| Drug | Indication | Phase | PTRS | rNPV | Status | Enroll | Velocity | Design | Est. Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|
| ALKS 7290 Small moleculeNCT07755410 | Attention Deficit Disorder With Hyperactivity (ADHD) | Phase 2 | RECRUITING | 312 | Jul 1, 2027 |
Clinical Trial Results
Readouts, endpoints and source filings for every ALKS program
| Drug Name | Indication | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
| ALKS 7290 | Attention-Deficit Hyperactivity Disorder | Phase 1b | 2026-09-21 | n=88 in healthy volunteers and n=5 in adults with ADHDRead More | Alkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)Read More |
Inside Trades
| Insider | Side | Shares | Price | Value | Date |
|---|---|---|---|---|---|
| Gaffin David JosephOfficer (EVP, CLO, Alkermes, Inc.) | Sell | -2,034 221,388 held | $41.03 | 10/02/2026 |
Hedge Fund 13F Activity
Hedge Funds invested in ALKS
| Fund | % of Portfolio | Current MV | Shares Owned | Activity |
|---|---|---|---|---|
| BAKER BROS. ADVISORS | 2.6 % (30 %) | 524.59 M | 10.01 M |
ALKS Institutional Ownership Trends
Options Data
Option Volume
Open Interest
Call OI
Put OI
Put-Call Ratio
OI 30-day avg
Today vs avg
Option Volume
Call Vol
Put Vol
Put-Call Ratio
Vol 30-day avg
Today vs avg
Option Chain Statistics
| Expiry | Call Vol | Put Vol | Vol P/C | Call OI | Put OI | OI P/C | IV Call | IV Call OI-Wtd | IV Call Vol-Wtd | IV Put | IV Put OI-Wtd | IV Put Vol-Wtd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2027-01-15 | ||||||||||||
Real-Time Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last | Vol | OI | Last | Vol | OI | |
| No data available | ||||||
Calls vs Puts by Expiry
CallsPutsLog scale
Competitive positioning
How ALKS ranks across every disease it competes in
Competitive Position is a premium feature
See how ALKS ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trialALKS News
ALKSAlkermes Announces Positive Phase 1b Results Demonstrating Clinical Proof-of-Concept for ALKS 7290 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)
Alkermes plc has announced positive topline results from a Phase 1b study of ALKS 7290, a novel orexin 2 receptor agonist aimed at treating ADHD. The study assessed safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy volunteers and adults with ADHD. These results indicate a promising step forward in ADHD treatment options.
Read more →ALKSAlkermes Announces Appointment of Anne C. Whitaker to Board of Directors
Alkermes plc has appointed Anne C. Whitaker as an independent director on its Board of Directors. Ms. Whitaker is recognized for her extensive experience in the biopharmaceutical sector, contributing valuable commercial and operational insights. Her appointment is seen as timely for the company's growth and transformation efforts.
Read more →ALKSAlkermes Announces Launch of 9th Annual Alkermes Pathways Research Awards® Program
Alkermes plc has announced the launch of its 9th annual Alkermes Pathways Research Awards program, which will begin accepting applications on September 11, 2026. This competitive grant program aims to support emerging researchers focused on advancing knowledge in neuroscience. The initiative builds on previous cycles to foster innovative research.
Read more →ALKSThe Lancet Neurology Publishes Data From Alkermes’ Positive Vibrance-1 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 1
Alkermes plc has announced the publication of positive data from the Vibrance-1 phase 2 study of alixorexton, an investigational treatment for narcolepsy type 1, in The Lancet Neurology. Alixorexton is a selective orexin 2 receptor agonist, also being developed for narcolepsy type 2 and idiopathic hypersomnia. The study results support its potential efficacy in treating these conditions.
Read more →ALKSAlkermes plc Reports Second Quarter 2026 Financial Results
Alkermes plc has announced its financial results for the second quarter of 2026. The company will host a conference call and webcast to discuss these results and future expectations. Investors can access the detailed earnings press release on the company's investor relations website.
Read more →ALKSAlkermes to Report Second Quarter Financial Results on July 28, 2026
Alkermes plc is set to report its second quarter financial results on July 28, 2026. The company will host a conference call and webcast presentation to discuss these results, demonstrating its commitment to investor communication. Interested parties can access the webcast on Alkermes' website or join via phone.
Read more →ALKSAlkermes’ Alixorexton Demonstrated Sustained Improvement in Wakefulness in Adults With Narcolepsy Type 1 and Type 2 in Long-Term Extension Study Interim Analysis
Alkermes plc announced positive interim results from a long-term extension study of alixorexton, showing significant improvements in wakefulness for adults with narcolepsy type 1 and type 2. The study measured outcomes using the Maintenance of Wakefulness Test and the Epworth Sleepiness Scale. Results indicate that alixorexton may provide meaningful benefits for patients.
Read more →ALKSAlkermes Presents Detailed Positive Results From Vibrance-2 Phase 2 Study of Alixorexton in Adults With Narcolepsy Type 2 at SLEEP 2026
Alkermes has reported positive findings from the Vibrance-2 Phase 2 study of Alixorexton, targeting adults with Narcolepsy Type 2. The results were showcased at the SLEEP 2026 conference, highlighting the potential of Alixorexton as a treatment option. This development marks a significant step forward in addressing Narcolepsy Type 2.
Read more →ALKSAlkermes Announces Orphan Drug Designations for Alixorexton in the U.S. and Europe
Alkermes has announced that Alixorexton has received orphan drug designations in both the U.S. and Europe. This designation is intended to facilitate the development of the drug for rare diseases. The announcement highlights Alkermes' commitment to addressing unmet medical needs in these regions.
Read more →ALKSAlkermes to Present New Data on Alixorexton and LUMRYZ® (sodium oxybate) at SLEEP 2026, Highlighting Breadth of Sleep Medicine Research
Alkermes plc announced its participation in SLEEP 2026, where it will present new data on Alixorexton and LUMRYZ. The company will showcase 26 abstracts, including positive results from the Vibrance-2 Phase 2 study of Alixorexton for narcolepsy type 2. This event underscores Alkermes' commitment to enhancing treatment options for sleep disorders.
Read more →ALKSAlkermes to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference
Alkermes is set to participate in the Goldman Sachs 47th Annual Global Healthcare Conference. The event will provide a platform for the company to discuss its strategies and developments in the biopharma sector. Further details about the conference and Alkermes' involvement have not been disclosed.
Read more →ALKSAlkermes to Showcase Leadership in Psychiatry and Orexin Biology With New Data at the American Society of Clinical Psychopharmacology Annual Meeting
Alkermes is set to present new data at the American Society of Clinical Psychopharmacology Annual Meeting, highlighting its leadership in psychiatry and orexin biology. This event will showcase the company's advancements and contributions to the field. Details regarding the specific data to be presented were not disclosed in the article.
Read more →ALKSAlkermes Showcases Data From Psychiatry Portfolio and Sleep Research into Real World Patient Experience at Spring 2026 Scientific Conferences
Alkermes presented data from its psychiatry portfolio and sleep research at scientific conferences in Spring 2026. The focus was on real-world patient experiences, highlighting the company's commitment to understanding patient needs and outcomes in these therapeutic areas. The event showcased the latest findings and advancements in their research efforts.
Read more →ALKS▲ +8%on this news
Alkermes Announces Positive Topline Results From REVITALYZ℠ Phase 3 Study Evaluating LUMRYZ® (sodium oxybate) Extended-Release in Adults With Idiopathic Hypersomnia
Alkermes has announced positive topline results from its REVITALYZ Phase 3 study, which evaluated LUMRYZ (sodium oxybate) extended-release in adults with idiopathic hypersomnia. The study's findings suggest that LUMRYZ may be an effective treatment option for this condition, potentially enhancing the quality of life for affected individuals.
Read more →ALKS▲ +8%on this news
Alkermes Contacts: For Investors: Sandy Coombs +1 781 609 6377 For Media: Gretchen Murphy +1 781 609 6419 Alkermes Announces Positive Topline Results From REVITALYZ SM Phase 3 Study Evaluating LUMRYZ (sodium oxybate) Ext
Alkermes plc announced positive topline results from the Phase 3 REVITALYZ study evaluating LUMRYZ (sodium oxybate) in adults with idiopathic hypersomnia. The study showed statistically significant and clinically meaningful improvements in excessive daytime sleepiness, meeting all primary and key secondary endpoints. The results suggest LUMRYZ could serve as an effective treatment for this patient population, which lacks adequate therapy options. Alkermes plans to file a supplemental New Drug Application with the FDA following these positive outcomes.
Read more →ALKS▲ +6.1%on this news
Alkermes plc Reports First Quarter 2026 Financial Results
Alkermes plc has reported its financial results for the first quarter of 2026, revealing revenues of $392.9 million despite a GAAP net loss of $66.5 million. The company successfully completed the acquisition of Avadel Pharmaceuticals, which is expected to bolster its entry into the sleep medicine market. Additionally, Alkermes has initiated a Phase 3 clinical program for alixorexton, affirming its commitment to advancing treatments for narcolepsy. While the adjusted EBITDA has shown improvement, significant operating losses suggest challenges remain.
Read more →ALKSAlkermes to Report First Quarter Financial Results on May 5, 2026
Alkermes plc will host a conference call on May 5, 2026, to discuss its first quarter financial results. The event will be accessible via a webcast and phone call for both U.S. and international participants. The company, focused on neuroscience, has a diverse portfolio and an active pipeline of clinical candidates.
Read more →ALKSAlkermes to Present Additional Data From Vibrance-1 Phase 2 Study of Alixorexton in Patients with Narcolepsy Type 1 at the American Academy of Neurology (AAN) 2026 Annual Meeting
Alkermes will present additional data from the Vibrance-1 Phase 2 study of Alixorexton, focusing on its effects in patients with Narcolepsy Type 1. This presentation is scheduled for the American Academy of Neurology (AAN) 2026 Annual Meeting. The details of the findings have not been disclosed yet.
Read more →About Alkermes plc
HeadquartersCONNAUGHT HOUSE, DUBLIN 4, L2, 00000
Founded2011
BIOPHARMAWATCH ELITE PLUS
Trade the next ALKS catalyst before the market reprices
Every FDA decision, PoA score, 13F move and dilution flag on this page, for 1,100+ biotech tickers. From $19/mo billed annually.
Cancel anytime